Innovative Therapeutics Igenica Biotherapeutics specializes in antibody-based therapies and antibody-drug conjugates aimed at treating cancer, suggesting opportunities for collaborations in immunotherapy and targeted cancer treatments.
Growing Funding With a total funding of $71 million and multiple successful funding rounds, Igenica demonstrates strong investor support, which may lead to accelerated research and potential for new partnership opportunities in biotech innovations.
Research Expertise The company's focus on first-in-class antibodies and its strategic hires of high-level scientific personnel position it as a leader in innovative cancer therapeutics, making it a valuable partner for advanced biotech solutions and research collaborations.
Niche Market Focus Igenica operates in the specialized area of cancer immunotherapies with a targeted pipeline, providing sales opportunities in niche biotech components, research tools, and supportive therapeutic technologies tailored for oncology.
Strategic Positioning Being a mid-sized company backed by prominent investors and positioned in the highly competitive biotech landscape presents chances for complementary technologies, research partnerships, and supply chain collaborations to scale therapeutic development.
$10B
$10B
$10B
$10B
$10B
$10B
$10B
$10B
$10B
$10BIgenica Biotherapeutics, Inc. uses 8 technology products and services including Facebook Pixel, Hotjar, WordPress, and more. Explore Igenica Biotherapeutics, Inc.'s tech stack below.
| Igenica Biotherapeutics, Inc. Email Formats | Percentage |
| FLast@igenica.com | 33% |
| First@igenica.com | 17% |
| First-Last@igenica.com | 17% |
| FLast@igenica.com | 33% |
Biotechnology ResearchCalifornia, United States11-50 Employees
Igenica Biotherapeutics is focused on the discovery of innovative antibody-based therapies for the treatment of cancer. Igenica’s integrated discovery engine has generated a novel pipeline of immunotherapies and ADCs that address the critical needs of cancer patients. Igenica is funded by a premier group of life science investors including The Column Group, OrbiMed, 5AM Ventures and Third Rock Ventures.
Company Overview
Media & News
Funding & FinancialsIgenica Biotherapeutics, Inc. has raised a total of $71M of funding over 3 rounds. Their latest funding round was raised on Jan 28, 2014 in the amount of $14Mas a Series C.
Igenica Biotherapeutics, Inc.'s revenue is estimated to be in the range of $1M$10M
Funding & FinancialsIgenica Biotherapeutics, Inc. has raised a total of $71M of funding over 3 rounds. Their latest funding round was raised on Jan 28, 2014 in the amount of $14Mas a Series C.
Igenica Biotherapeutics, Inc.'s revenue is estimated to be in the range of $1M$10M
1-888-653-2347 
support@leadiq.com